- Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
- Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
- Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
- Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
- Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
- Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
- Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
More ▼
Key statistics
As of last trade, Xenon Pharmaceuticals Inc (XENE:NMQ) traded at 38.43, 37.32% above the 52 week low of 27.99 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 38.20 |
---|---|
High | 38.61 |
Low | 37.93 |
Bid | 38.37 |
Offer | 38.52 |
Previous close | 38.10 |
Average volume | 435.58k |
---|---|
Shares outstanding | 75.47m |
Free float | 74.29m |
P/E (TTM) | -- |
Market cap | 2.87bn USD |
EPS (TTM) | -2.71 USD |
Data delayed at least 15 minutes, as of Jun 05 2024 17:51 BST.
More ▼